The present disclosure relates to a class of mammalian heat shock factor (HSF) inhibitors, to pharmaceutical compositions comprising these inhibitors as well as to methods for using the inhibitors. The inhibitors inhibit stress-induced expression from heat shock gene promoters. Furthermore, the inhibitors are cytotoxic to a variety of human cancer cells types.

The present invention provides an electroluminescent compound of one of following formulas Formula 1 and Formula 2. Another aspect of the invention is an electroluminescent device including a first electrode; a second electrode facing the first electrode; and at least one organic material layer between the first and second electrodes, wherein one or more of the at least one organic material layer includes the electroluminescent compound. ##STR00001##

The present invention provides an electroluminescent compound of one of following formulas Formula 1 and Formula 2. Another aspect of the invention is an electroluminescent device including a first electrode; a second electrode facing the first electrode; and at least one organic material layer between the first and second electrodes, wherein one or more of the at least one organic material layer includes the electroluminescent compound. ##STR00001##

Disclosed herein are compositions comprising air-stable radical [2]catenanes and method of making the same. The [2]catenane comprises a first macrocyclic ring mechanically interlocked with a second macrocyclic ring where each of the first macrocyclic ring and the second macrocyclic ring comprise an alternating cyclic arrangement of a first unsubstituted or substituted 4,4′-bipyridinium (BIPY) subunit, a first unsubstituted or substituted phenylene subunit, a second unsubstituted or substituted BIPY subunit, and a second unsubstituted or substituted phenylene subunit forming a macrocycle.

Disclosed herein are compositions comprising air-stable radical [2]catenanes and method of making the same. The [2]catenane comprises a first macrocyclic ring mechanically interlocked with a second macrocyclic ring where each of the first macrocyclic ring and the second macrocyclic ring comprise an alternating cyclic arrangement of a first unsubstituted or substituted 4,4′-bipyridinium (BIPY) subunit, a first unsubstituted or substituted phenylene subunit, a second unsubstituted or substituted BIPY subunit, and a second unsubstituted or substituted phenylene subunit forming a macrocycle.

The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to multiple-component phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions.

The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to multiple-component phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions.

Compounds of formula (I) and related aspects.

##STR00001##

An organic compound represented by General Formula (1),

##STR00001##

in which, in General Formula (1), R.sub.1 represents an alkyl group or an alkoxy group, X.sub.1 and X.sub.2 are each independently selected from an alkyl group which may have a substituent, an aryl group which may have a substituent, or an aralkyl group which may have a substituent, and A.sub.1.sup.− and A.sub.2.sup.− each independently represent a monovalent anion.

An organic compound represented by General Formula (1),

##STR00001##

in which, in General Formula (1), R.sub.1 represents an alkyl group or an alkoxy group, X.sub.1 and X.sub.2 are each independently selected from an alkyl group which may have a substituent, an aryl group which may have a substituent, or an aralkyl group which may have a substituent, and A.sub.1.sup.− and A.sub.2.sup.− each independently represent a monovalent anion.